Table 3 Parameters evaluated at central precocious puberty diagnosis and at follow-up according to the later diagnosis of polycystic ovarian syndrome (PCOS)
Parameter | PCOS N = 10 | No PCOS N = 41 | P value |
|---|---|---|---|
Age at CPP diagnosis (years) | 8.1 ± 1.2 (6.8–10.0) | 8.5 ± 1.0 (5.7–10.6) | 0.360 |
Bone age at CPP diagnosis (years) | 10.1 ± 1.8 (7.1–12.0) | 10.2 ± 1.8 (7.1–13.0) | 0.982 |
Advanced over chronological age (months) | 21.0 ± 17.3 (5.0–50.0) | 18.7 ± 10.9 (0–43.0) | 0.928 |
BMI percentile at CPP diagnosis | 83.5 ± 11.1 (65.0–95.0) | 76.8 ± 23.9 (1.0–98.9) | 0.988 |
Fetal | 0.151 | ||
Appropriate for gestational age | 9 (90.0) | 36 (87.8) | |
Small for gestational age | 0 | 5 (12.2) | |
Large for gestational age | 1 (10.0) | 0 | |
Prematurity (< 37 weeks) | 1 (10.0) | 4 (9.8) | 1.00 |
Clinical presentation at CPP diagnosis | 0.367 | ||
Pubarche and thelarche | 5 (50.0) | 26 (70.3) | |
Thelarche | 3 (30.0) | 7 (18.9) | |
Pubarche | 2 (20.0) | 4 (10.8) | |
LH at CPP diagnosis (IU/L) | 2.1 ± 1.9 (0.1–6.0) | 2.0 ± 1.5 (0.1–6.2) | 0.925 |
FSH at CPP diagnosis (IU/L) | 4.0 ± 2.4 (1.40–8.3) | 4.3 ± 2.1 (1.1–9.4) | 0.625 |
Estradiol at CPP diagnosis (pmol/L) | 203.3 ± 160.5 (70–518) | 150.0 ± 193.7 (70–1080) | 0.140 |
LH/FSH ratio at CPP diagnosis | 0.6 ± 0.3 (0.1–1.0) | 0.5 ± 0.3 (0.1–1.4) | 0.479 |
GnRH analogue treatment for CPP | 6 (60.0) | 21 (51.2) | 0.735 |